RA Capital

ANTHONY ARCECI, PhD

Associate

Anthony Arceci is an Associate with the TechAtlas division of RA Capital Management. Anthony’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to RA, Anthony completed the Biopharmaceutical Leadership Development Program at Reata Pharmaceuticals. Anthony has a BS in Molecular and Cellular Biology from University of Arizona and a PhD in Genetics and Molecular Biology from University of North Carolina at Chapel Hill.

DANIEL BAHCHELI

Associate Director

Daniel Bahcheli is an Associate Director at RA Capital Management. Daniel’s primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Daniel holds both a BS and MS degree in Microbiology and Immunology from McGill University. He worked previously as an Associate Managing Editor at EBSCO Health, and as a Medical Writer at IC Axon and Publicis Life Brands International.

PETER BALOGH

Senior Associate

Peter Balogh is a Senior Associate within the TechAtlas division of RA Capital Management. Peter’s primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill.

MATT BEVERLY, PhD

Senior Software Engineer

Matt Beverly is a Senior Software Engineer at RA Capital Management. Matt’s primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Matt has a BA in Biology with minors in Mathematics and Physics from Ithaca College, a Master of Science in Bioinformatics from Northeastern University, and a PhD in Molecular Biology with a specialization in quantitative biology from Brandeis University. Matt comes to RA from Localytics where he served as a Senior Software Engineer for the past two years. Prior to Localytics, Matt served as software engineer at Mathworks.

DREW BIEDERMANN, PhD

Associate

Drew Biedermann is an Associate with the TechAtlas division of RA Capital Management. Drew’s primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to RA, Drew gained experience in Data Science in Technical Consultant roles at ExxonMobil. Drew has a BS in Chemical Engineering from University of Virginia and a PhD in Chemical Engineering from Massachusetts Institute of Technology.

ASTHA BILIMORIA

Data Analyst Associate

Astha is a Data Analyst Associate at RA Capital Management. Astha’s primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Astha’s previous experience includes Research Assistant roles at Clark University and Corbus Pharma. Astha holds a BA in Biochemistry and Molecular Biology (with a minor in Physics) from Clark University.

ANA CASTRO

Senior Research Assistant, Venture Analytics

Ana is a Senior Research Assistant, Venture Analytics at RA Capital Management. Ana’s primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Ana’s previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University.

SAMUEL CHOWDHURY

Software Engineer

Samuel Chowdhury is a Software Engineer at RA Capital Management. Sam’s primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a BS in Computer Engineering and a Minor in Mathematics from Northeastern University.

ERIN CLUTTER

Head of Graphics

Erin Clutter is the Head of Graphics at RA Capital Management. Erin’s primary responsibilities at RA Capital are to manage the design and creation of all internal and external documents and resources for the company, including competitive landscapes of drugs and medical devices for disease indications and capabilities, set brand standards, and oversee internal and external marketing efforts. Erin holds a Bachelor of Fine Arts degree from the Massachusetts College of Art & Design. She worked previously in desktop publishing and as a freelance designer.

MEREDITH COLLINS

Research Assistant

Meredith is a Research Assistant at RA Capital Management. Meredith’s primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Meredith’s previous experience includes Medical Education Researcher and Medical Scribe positions at BMC Global Inc. and Longwood Pediatrics, respectively. Meredith holds a BS in Biology: Pre-Med from the University of North Carolina at Charlotte.

ANDREW COSTENOBLE

Software Developer

Andrew is a Software Developer at RA Capital Management. Andrew’s primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a BS in Computer Science from Northeastern University.

CAMERON DECKER

Research Assistant

Cameron is a Research Assistant at RA Capital Management. Cameron’s primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Prior to RA, she served as Researcher and Collaborator at New Care, a startup focused on improving access to early childcare for lower income families. Before her time at New Care, she was a Student Researcher at Boston Children’s Hospital Labs of Cognitive Neuroscience. Cameron has a BA in Neurobiology from Harvard University.

MAX DENIES, PhD

Associate

Max DeNies is an Associate with the TechAtlas division of RA Capital Management. Max’s primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Max has a BS in Biology from the State University of New York at Fredonia and a PhD in Cellular and Molecular Biology from the University of Michigan.

MATT FERESTEN

Business Systems Analyst

Matthew Feresten is a Business Systems Analyst at RA Capital Management. Matt’s primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. He holds a BS in Biology from the College of William and Mary, where he studied the impact of ecological fragmentation on the prevalence of ticks and their bacterial pathogens.

MICHAEL GILLESPIE, MD

Senior Associate

Michael Gillespie is a Senior Associate within the TechAtlas division of RA Capital Management. primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Michael's previous experience includes venture development at Health Wildcatters Seed Accelerator and product development in various roles at the Institute for Environmental and Exercise Medicine and as an Aerospace Medicine Clerk at NASA. Michael holds a BS in Exercise Science from Brigham Young University and an MD from the University of Texas Southwestern School of Medicine.

EMILY GREEN

Visual Identity Designer

Emily Green is a Visual Identity Designer at RA Capital Management. Emily’s primary responsibility at RA Capital is designing and overseeing the brand management for RA Capital's internal and external communications as well assisting with the brand identity for portfolio companies founded through RA Capital's incubator, RA Ventures. Emily holds a BS in Graphic Design from James Madison University.

JENNA HEBERT, PhD

Associate

Jenna Hebert is an Associate within the TechAtlas division of RA Capital Management. Jenna’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Jenna previously held roles as Senior Medical Writer and Analyst at Costello Medical Consulting. Jenna has a B.A. in Neuroscience from University of Pennsylvania and a PhD in Neuroscience from University of Oxford.

PEYMAN HOSSEINCHI, PhD

Associate

Peyman Hosseinchi is an Associate within the TechAtlas division of RA Capital Management. Peyman’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Peyman holds a dual B.S. in Mechanical & Aerospace Engineering from Sharif University of Technology, Tehran, Iran and a PhD in Molecular Engineering from Pritzker School of Molecular Engineering, University of Chicago.

SONIA KARTHA, PhD

Associate

Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. Sonia’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Sonia has a BA in Chemistry and a PhD in Bioengineering, both from the University of Pennsylvania.

JAIMIE KIRKPATRICK

Research Assistant

Jaimie Kirkpatrick is a Research Assistant at RA Capital Management. Jaimie's primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Jaimie previously held roles as data analyst at Massachusetts Department of Public Health and Anne Arundel Medical Center Department of Medicine. Jaimie holds a BA in Biology Boston College, with Minors in Medical Humanities and Sociology, and a Master of Public Health from Boston University School of Public Health.

TYLER KOWALSKI

Interactive Designer

Tyler Kowalski is an Interactive Designer at RA Capital Management. Tyler’s primary responsibility at RA Capital is designing and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. In addition, he designs graphics for all internal and external materials. Prior to RA Capital, Tyler worked as a freelance graphic designer. Tyler holds a BA in Finance from the University of Massachusetts, Amherst.  

CHRISTY KUO, PhD

Associate

Christy is an Associate with the TechAtlas division of RA Capital Management. Christy’s primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. She was also an Entrepreneurial Fellow at VentureLabs for Flagship Pioneering. Christy has an MS in Immunology from National Taiwan University, a PhD in Immunology and Microbial Pathogenesis from Cornell University, and a mini-MBA in BioPharma Innovation from Rutgers Business School.

ALYSSA LARSON, PhD

Associate Director

Alyssa Larson is an Associate Director within the TechAtlas division at RA Capital Management. Alyssa’s primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to this role, Alyssa mapped a number of competitive landscapes of drugs and medical devices for disease indications and capabilities. Alyssa holds a BS in Biochemistry from the University of California, Santa Barbara, and a PhD in Biochemistry from MIT. Her graduate research investigated inhibitors of influenza virus and characterizing hydrophobic polycationic antimicrobial surfaces. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals.

PRISCILLA LEE, PhD

Associate

Priscilla Lee is an Associate within the TechAtlas division of RA Capital Management. Priscilla’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Priscilla previously held a Senior Scientist role at Sanofi. Priscilla has a B.S. in Life Science from National Taiwan University, M.S. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University.

CHRISTINA LILLIEHOOK, PhD

Senior Science Writer

Christina is a Senior Science Writer at RA Capital Management. Christina’s primary responsibility is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Christina’s previous experience includes Stem Cell Program Manager at the Broad Institute and Deputy Editor at Cell Stem Cell. Christina holds a PhD in Neuroscience from the Ichan School of Medicine at Mount Sinai and a BS in Biochemistry from Stockholm University.

JON LUNDT, PhD

Senior Associate

Jon Lundt is a Senior Associate within the TechAtlas division of RA Capital Management. Jon's primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Jon has a PhD in Biomedical Engineering from the University of Michigan, an MS in Mechanical Engineering from Boston University, and a BS in Physics from the University of Washington.

SRI MAHENDRA

Senior Software Engineer

Sri Mahendra is a Senior Software Engineer at RA Capital Management. Sri’s primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a Bachelor’s degree in Electronics and Communications from Anna University, and a Master’s degree in Computer Science from Northeastern University. He previously worked as a Software Engineer for several companies, including Autodesk, the Advisory Board Company, and Maveric Systems.

IRA MALE, PhD

Associate

Ira is an Associate with the TechAtlas division of RA Capital Management. Ira’s primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Ira has a BS in Biology with a minor in Chemistry from Worcester State College and a PhD in Molecular and Cellular Biology from the University of Massachusetts, Amherst.

DAVID MIGL, PhD

Senior Associate

David is a Senior Associate within the TechAtlas division of RA Capital Management. David’s primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. David holds a PhD from Harvard University in Biophysics and a BS in Molecular Biology from Texas A&M University.

CRISTINA MONTERO, PhD

Associate Director

Cristina Montero is an Associate Director within the TechAtlas division of RA Capital Management. Cristina’s primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to this role, Cristina mapped a number of competitive landscapes, including respiratory, allergic, and infectious disease conditions. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription.

KATE MOREAU, PhD

Associate Director

Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. Kate’s primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to this role, Kate worked with the Venture team evaluating early stage investment opportunities and mapped a number of competitive landscapes, including ophthalmology, lower GI, and non-viral liver disease. Kate holds a BA in Molecular Biology and Biochemistry from Rutgers University, and a PhD in Biochemistry from MIT. Her doctoral research investigated the folding and aggregation of gamma-crystallins associated with cataract formation.

FUAD NASER, PhD

Associate

Fuad Naser is an Associate with the TechAtlas division of RA Capital Management. Fuad’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to RA, Fuad was a Flagship Labs Fellow at Flagship Pioneering. Fuad has a BA in Biology with a Minor in Psychology and earned a PhD in Biological Chemistry, both from Washington University in St. Louis.

JOSH PARKER

Research Assistant

Josh is a Research Assistant at RA Capital Management. Josh’s primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. Prior to that, he was a Life Sciences Investment Associate at Brigham Capital. Josh holds a BS in Genetics, Genomics, and Biotechnology with a Minor in Business from Brigham Young University.

JONATHAN PRITZ, PhD

TechAtlas Analyst

Jonathan Pritz is an Analyst within the TechAtlas division at RA Capital Management. Jonathan’s primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs, support investment diligence and company creation, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Jonathan holds a BS in Microbiology and Cell Science from the University of Florida, and a PhD in Biological Chemistry and Molecular Pharmacology from Harvard University. His graduate research investigated chemical activators of cell death in cancer.

JACQUELINE RHUDA

Data Analyst Associate

Jacqueline a Data Analyst Associate at RA Capital Management. Jacqueline’s primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Prior to RA, she spent two years as a Research Intern and Teaching Assistant at Johns Hopkins University, Department of Biology and the Department of Chemistry. Jacqueline has a BS in Molecular and Cellular Biology from John Hopkins University.

ROOZBEH RIAHI

Associate

Roozbeh Riahi is an Associate within the TechAtlas division of RA Capital Management. Roozbeh’s primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Roozbeh has a BS in Neuroscience from UCLA.

ERICH SCHELLER, PhD

Director of TechAtlas

Erich Scheller is the Director of the TechAtlas division of RA Capital Management. Erich’s primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Prior to this role, Erich mapped a number of competitive landscapes including lung cancer, obesity, and chronic kidney disease. Erich holds a BA in English Literature and Language from Harvard University and a PhD in Microbiology from the University of North Carolina, Chapel Hill. His graduate research investigated the role of fimbria in Bordetella adherence and virulence.

REBECCA SILBERMAN, PhD

Associate

Rebecca Silberman is an Associate with the TechAtlas division of RA Capital Management. Rebecca’s primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Becca has a BA in Biology from Colgate University and a PhD in Biology from MIT.

MONICA STANCIU, PhD

Associate Director

Monica Stanciu is an Associate Director within the TechAtlas division at RA Capital Management. Monica’s primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Monica previously worked as a Licensing Manager at Partners HealthCare Innovation. Monica holds a BSc in Neuroscience and Pharmacology from the University of Toronto and a PhD in Cancer Biology from MIT. Her graduate research investigated novel epigenetic regulators in glioblastoma.

ALEX STRASSER

Associate

Alex is an Associate with the TechAtlas division of RA Capital Management. Alex’s primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Alex has a BS in Chemistry and a Minor in Religious Studies from Davidson College.

HENRY STUSNICK

Junior Associate

Henry Stusnick is a Junior Associate at RA Capital Management. Henry’s primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to RA, Henry gained experience as an Investment Banking Analyst at SVB Leerink. Henry has a BA in Biology & Economics from Dartmouth College.

KRITI SUBRAMANYAM, PhD

Associate

Kriti Subramanyam is an Associate within the TechAtlas division of RA Capital Management. Kriti’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Kriti previously served as Co-Director and Regional Director, South Asia for MIT Hacking Medicine. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital.  Kriti holds a B.S. in Engineering Sciences in Bioengineering from Harvard University and a PhD in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology (HST) Program.

KALEEN SULLIVAN

Senior Project Coordinator Associate

Kaleen Sullivan is a Senior Project Coordinator Associate at RA Capital Management. Kaleen’s primary responsibility is to oversee the initiation, planning, and execution of various projects within the TechAtlas Division. She holds a BBA in Marketing from Loyola University Maryland.

DING SUN

Senior Software Engineer

Ding Sun is a Senior Software Engineer at RA Capital Management. Ding’s primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a BS in Computer Science from The University of California, San Diego, and worked previously as a Software Engineer at IBM and Fidelity Investments.

KATHERINE TERRANOVA

Associate

Katherine Terranova is an Associate within the TechAtlas division of RA Capital Management. Katherine’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Katherine has a as a BA in Mathematics and a Minor in Chemistry from Boston College and a Master of Science in Medical Science from Boston University School of Medicine.

ABHISHEK THAKAR

Data Analyst Associate

Abhishek is a Data Analyst Associate at RA Capital Management. Abhishek's primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Abhishek gained experience using data analytics to track and visualize patient testing in his most recent role at Blueprint Medicines. Prior to Blueprint Medicines, he spent two years at Lonza Pharma & Biotech, most recently as Product Development Scientist. Abhishek has a BS in Bioproducts and Biosystems Engineering and a BS in Chemistry from University of Minnesota, Twin Cities. He earned his MS in Bioinformatics from Boston University.

MICHAEL VARNUM

Research Assistant

Michael Varnum is a Research Assistant at RA Capital Management. Michael’s primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Michael holds a B.S. in Business Administration in Management with a Minor in Biology from UMass Amherst Commonwealth Honors College. 

SHAN SHAN WANG, PhD

Senior Associate

Shan Shan is a Senior Associate within the TechAtlas division of RA Capital Management. Shan Shan’s primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Shan Shan holds a PhD in Neuroscience from Harvard University and a BS in Brain and Cognitive Sciences from MIT.

PIETER BOELHOUWER

Partner and Managing Director

Pieter Boelhouwer is a Partner and Managing Director of Strategy and Operations at RA Capital Management. Pieter’s primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Pieter holds a BA from Trinity College and a JD from Yale Law School. Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions. He held senior management positions at two successful start-up companies that were acquired and he has over 14 years of experience investing in the global healthcare sector, both as a Partner and Managing Director at Matrix Capital Management and as a General Partner and Managing Director at Ayer Capital Management, a healthcare-focused hedge fund. He also gained extensive legislative and public policy experience early in his career as a Legislative Aide to former United States Senator David Boren, and as a Domestic Policy Advisor to former Vice President Al Gore. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation.

ADISON BECKER

Executive Assistant

Adison is an Executive Assistant RA Capital Management. Adison’s primary responsibilities are to coordinate calendars, events, and company meetings for the Investment Team. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. She has a BA in Communication Studies from University of Minnesota, Twin Cities.

BRIAN BENNETT

IT Operations Lead

Brian is IT Operations Lead at RA Capital Management. Brian's primary responsibility at RA Capital is to manage the firm's IT Operations needs. Brian previously worked at the Kraft Group LLC, where he led their system admin, network, and desktop engineering groups. Brian has a B.S. in Business Administration in Management Information Systems from Northeastern University.

JEFF BREAY

Head Trader

Jeff Breay is a Head Trader at RA Capital Management. His responsibilities include managing the portfolio’s public equity positions, monitoring market, sector, and individual equity dynamics, and maintaining relationships with broker/dealer counterparties. Jeff holds a BA in Economics and Psychology from Georgetown. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office.

AMBER BROWN

Senior Executive Assistant

Amber is Senior Executive Assistant at RA Capital Management. Her primary responsibilities are to coordinate calendars, events, and company meetings. She previously held Executive Assistant and Senior Executive Assistant roles at Genuity Science, Charles River Laboratories, and Gloucester Graphics, Inc. Amber has a dual BA concentration in International Business & Modern Languages from Northeastern University and studied abroad at American University of Paris.

CHRIS CALIRI

Chief Information Officer

Chris Caliri is the Chief Information Officer at RA Capital Management. Chris’ primary responsibility at RA Capital is to oversee the firm’s information technology program, including operations, development, and security. He holds a Master’s degree in Software Engineering from Brandeis University and a BA in Psychology from Providence College. He worked previously as the Director of Business Systems at Bain Capital Credit, and as a Senior Systems Analyst at eSecLending, LLC.

MICHAEL CALORE

Director of Investor Relations

Michael Calore is the Director of Investor Relations at RA Capital Management. Michael’s primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. He was previously a marketing manager at Brighton House Associates, assisting with fundraising campaigns for a diverse group of investment managers, including private equity, venture capital, real estate, and hedge funds. He holds a BS in Finance from Providence College.

HARVEY CHAN

Controller

Harvey is a Controller at RA Capital Management. Harvey’s primary responsibility is to oversee all accounting related activities for the firm. Harvey most recently served as Assistant Controller at Charles River Ventures. His prior posts include Fund Accountant at Nautic Partners and HLM Venture Partners. Harvey holds an MS in Finance from Bentley University McCallum Graduate School of Business and a BS in Corporate Finance and Accounting from Bentley University.

LORENA CHEN, CPA

Fund Controller

Lorena Chen is a Fund Controller at RA Capital Management. Lorena's primary responsibility is to oversee all accounting related activities for the firm. She has spent the last five years as a Senior Finance Associate at Great Hill Partners. Prior to GHP, Lorena served as an Assurance Senior at EY. Lorena has dual degrees from Beijing Foreign Studies University: a Bachelor of Business Administration in Accounting and a Bachelor of Arts in English Literature. She also has a Master's in Accounting from Boston College and is a CPA.

LAURA CLOSE

Executive Assistant

Laura is an Executive Assistant at RA Capital Management. Laura’s primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. Laura previously worked at WinterWyman where she served as a Senior Associate.

EBONY COTTERELL

Payroll and Benefits Manager

Ebony is the Payroll and Benefits Manager at RA Capital Management. Her primary responsibilities are to manage payroll and benefit programs for the company. Ebony previously worked as Payroll and Benefits Manager at Not Your Average Joe's, where she led open enrollment, reporting, payroll, and benefits management for the company. Prior to Not Your Average Joe's, Ebony held roles in payroll and human capital management, as well as banking at Solex HCM and Rockland Trust Bank. Ebony is both a SHRM-Certified Professional (SHRM-CP) and an APA-Certified Payroll Professional (CPP).

DAVID CROWE

Director of Treasury

David is Director of Treasury at RA Capital Management. David’s primary responsibility is to oversee the development and implementation of treasury functions for the firm. Most recently, David served as Director of Operations at Corbin Capital Partners, LP. Prior to that, David worked as Director of Operations for Wingspan Investment Management, LP and held operations positions at Brencourt Advisors and Silver Point Capital, LP. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder.

KLIO DiCENZO

Chief People Officer

Klio DiCenzo is the Chief People Officer at RA Capital Management. Klio’s primary responsibilities at RA Capital are to oversee talent development, recruiting, people operations, and culture. Klio also partners with portfolio companies to provide guidance and thought leadership and to support the creation of HR procedures and programs. Klio previously worked as Human Capital leader at athenahealth where she helped build and scale their commercial business unit; during her time there she oversaw the hiring of over 300 employees, the implementation of core HR processes and programs, and the organizational design to accommodate athenahealth’s rapid growth. Prior to athenahealth, Klio held various HR leadership positions at PricewaterhouseCoopers within their consulting, audit, and tax practices where she focused on compensation and employee experience. She holds a Master of Arts in Teaching and a BA in Psychology, both from Simmons University.

JOHN DiNAPOLI

Systems Administrator

John DiNapoli is the Systems Administrator at RA Capital Management. John’s primary responsibility at RA Capital is to provide technical assistance and support for issues related to computer systems, the network, and server environments. John holds a BA in Sociology and Criminal Justice from the University of Massachusetts, Amherst. He previously worked as a Help Desk Manager at Toast.

CAT FLAHERTY

Executive Assistant

Cat is an Executive Assistant at RA Capital Management. Cat’s primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the Investment Division. Cat previously held posts as an Executive Assistant at Draper Richards Kaplan Foundation and Bain Capital. She has a BA in Liberal Studies from Endicott College and a Certificate in Interior Design from Parsons School of Design.

CANDICE GALVEZ

Executive Assistant

Candice Galvez is an Executive Assistant at RA Capital Management. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Candice has a BS in Mass Communications from Emerson College. Candice previously worked as the Director of Executive Office and Administration at Flywire. Prior to Flywire, she worked as an Executive/Personal Assistant at Spark Capital.

ERNESTO GONZALEZ

Senior Business Systems Analyst

Ernesto Gonzalez is a Senior Business Systems Analyst at RA Capital. Ernesto’s primary responsibility at RA Capital is to coordinate various technology related initiatives across the company and oversee their initiation, planning, and execution. He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. He holds a BA in History from University of Massachusetts, Amherst and a Master's of Urban Affairs from Boston University.

LUCAS GUEVARA

Compliance Counsel

Lucas Guevara is a Compliance Counsel at RA Capital Management. Lucas’ primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Lucas holds a BA in Criminal Justice and Philosophy from John Jay College of Criminal Justice in NY, a JD, Privacy Concentration, from Northeastern University School of Law, and is admitted to practice law in MA. Lucas previously held Law Clerk positions at The Community Builders, Inc. and at Nixon Peabody LLP.

NIKKI HECHT

Human Resources Generalist

Nikki is a Human Resources Generalist at RA Capital Management. Nikki’s primary responsibilities at RA Capital are to assist in full cycle talent management and recruiting. Nikki previously worked as a Human Resources Manager, Office Manager and Executive Assistant at the State Services Organization in Washington, DC. She has also held roles in Marketing and Client Services at West, Lane & Schlager and CBRE respectively. Nikki has a BA in Communication Studies from Christopher Newport University and is a HRCI-certified Professional in Human Resources (PHR).

LE HO

Business Systems Analyst

Le Ho is a Business Systems Analyst at RA Capital Management. Le’s primary responsibility is to coordinate various technology related initiatives across the company. She previously held roles as a Senior Business Analyst at Cambridge Associates and a Systems Analyst at Wellington Management Company. She holds a BA in Public Administration with a minor in International Affairs from Texas State University.

MARIAGRACE HOULLAHAN

Executive Assistant

Mariagrace Houllahan is an Executive Assistant at RA Capital Management. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Mariagrace has a BS in Sociology from Suffolk University. Mariagrace previously worked as an Executive Assistant at MPM Capital. Prior to MPM, she worked as an Executive Assistant at Charles River Ventures.

BRENDAN JOYCE

Tax Director

Brendan is a Tax Director at RA Capital Management. Brendan’s primary responsibility is managing all aspects of the tax function. Brendan has more than 16 years of experience as a tax professional. Most recently, Brendan served as Tax Director at PwC Asset & Wealth Management. Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. Brendan holds a BA in Economics with a concentration in Accounting & Marketing from University of Massachusetts Amherst and is an Enrolled Agent, admitted to practice before the IRS.

KATIE MAHER, PhD

Senior Compliance Officer

Katie Maher is a Senior Compliance Officer at RA Capital Management. Katie’s primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. She holds a BS in Biology from Pennsylvania State University and a PhD in Molecular and Cellular Biology from the University of Massachusetts, Amherst. Her doctoral work integrated molecular and genetic strategies to study the mechanism by which dopamine modulates neuronal activity in both individual neurons and neural circuits.

KATE MCKENNA

Compliance Coordinator and Paralegal

Kate McKenna is a Compliance Coordinator and Paralegal at RA Capital Management. Kate's primary responsibility is to work with both the Legal and Compliance Teams in support of their programs. Her contributions involve engagement with teams across RA Capital, including the processing of CDA's. Kate previously served as Health Law Assistant at Mintz. Prior to Mintz, Kate held a Paralegal role at Loughran & Corbett, Attorneys, Inc. Kate holds a Bachelor's Degree in Political Science from Bridgewater State University and is a certified Paralegal in Massachusetts.

BRITTANY McKINNON

Executive Assistant and Recruiting Coordinator

Brittany McKinnon is an Executive Assistant and Recruiting Coordinator at RA Capital Management. Brittany’s primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the Operations division as well as assist in all of the firm’s recruiting efforts. Brittany previously worked as a Delivery Specialist at Randstad Technologies. She holds a BA in Communications from Bryant University.

TOM MICHALIK, CFA, CAIA

Senior Operations Analyst

Tom is a Senior Operations Analyst at RA Capital Management. Tom’s primary responsibility is to support all aspects of trade and treasury operations. Tom has more than nine years of operations experience. Most recently, Tom served as Director of Operations at TPRV Capital, LP. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. Tom has a BA in Business Administration from St. Anselm College and earned both his Chartered Financial Analyst and Chartered Alternative Investment Analyst designations.

CHRIS MORRISON

Editor

Chris Morrison is an Editor at RA Capital Management. Chris’s primary responsibility at RA Capital is to cover the biotech and pharma industry. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products.

NICOLE NORTON

Office Manager

Nicole is an Office Manager at RA Capital Management. Nicole’s primary responsibilities are to coordinate office activities and operations. Nicole previously worked as a Business Systems Technician at Jacobs Engineering Group. She has also held roles in Marketing at RE/MAX, LLC and Aimco Properties. She holds a BS in Business Administration from Wayne State University.

JOEY O'NEILL

Investor Services Associate

Joey O’Neill is an Investor Services Associate at RA Capital Management. Joey’s primary responsibility is to manage workflows for investor transaction processing and investor reporting in collaboration with the fund's administrator. Joey previously served as Private Client Associate at Bernstein Private Wealth Management. Prior to Bernstein, Joey held a Consultant role at FactSet. Joey holds a Bachelor of Science in Finance from American University and is FINRA-certified in Series 7, Series 63 and Securities Industry Essentials.

CRAIG RANDALL

Associate Counsel

Craig Randall is Associate Counsel at RA Capital Management. Prior to RA, Craig has over five years of experience advising, counseling, and representing public and private companies in the Life Sciences, Digital Health, and Technology sectors in Corporate Associate roles at Foley Hoag LLP and Cooley LLP. Craig holds a BA in Political Science from Bridgewater State College, a JD from Boston College Law School, and is admitted to practice law in the Commonwealth of Massachusetts.

SARAH REED

General Counsel

Sarah Reed is the General Counsel at RA Capital Management. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. Prior to MPM, Sarah was the General Counsel for Charles River Ventures and before that, at Palomar Medical Technologies. Sarah began her legal career with Foley, Hoag, & Eliot LLP. Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. Sarah is the only lawyer to have received the NVCA’s Outstanding Service Award, for her leadership role in conceiving of and spearheading the NVCA Model Legal Documents. Sarah teaches a course at Harvard Law School on venture capital fund formation.

ERIC ROSE, MAcc, CFA, CPA

Chief Compliance Officer

Eric is the Chief Compliance Officer at RA Capital Management. Eric previously served as Director, Chief Risk and Compliance Officer, Americas at Aberdeen Asset Management. Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University.

RYAN RUSSELL

Fund Accountant

Ryan Russell is a Fund Accountant at RA Capital Management. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. Prior to RA, Ryan was at KPMG where he was a Senior Associate. Prior to KPMG, Ryan worked at Morris and Morris, P.C. as a Staff Accountant. Ryan has a BS in Business Administration with a concentration in Accounting and Sports Management from Isenberg School of Management at University of Massachusetts, Amherst.

MICHAEL SAULNIER, CPA

Chief Financial Officer

Michael is the Chief Financial Officer at RA Capital Management.He oversees the firm's financial functions, including audit, tax and regulatory.Prior to RA, Michael was a Special Projects Manager at Baupost, LLC. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP. Michael has also held leadership positions at Citigroup-HedgeFund Services in both Fund Accounting and Product Management before joining Centerbridge. Prior to Citigroup, Michael held various accountant and analyst roles at EY, Morgan Stanley, BBH, and Deloitte. Michael has a BS in Business Administration from Boston University with concentrations in Finance and Accounting. Michael is a CPA.

BRETT SCHELLER

Compliance Officer

Brett Scheller is a Compliance Officer at RA Capital Management. Brett’s primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA.

EMILIE SCHLEER

Senior Investor Relations Manager

Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Emilie’s primary responsibility at RA Capital is to manage current and potential investor relationships. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. Emilie has previously held similar roles at FLAG Capital Management and Bain Capital. She holds a BS in Finance from Elon University and an MBA from Babson College.

JAMES SCHNEIDER

Associate General Counsel

James Schneider is the Associate General Counsel at RA Capital Management. James’ primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. He previously worked as a corporate attorney at Foley Hoag LLP and Cooley LLP. James is admitted to practice law in the Commonwealth of Massachusetts.

DANIEL SLESINSKI

Associate, Climate Change Solutions

Daniel Slesinski is an Associate at RA Capital Management. Daniel’s primary responsibility a is to create competitive landscapes of climate change solutions. Daniel previously interned with the Center for Climate and Energy Solutions where he focused on the fusion energy market. Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University.

PHI THACH

Executive Assistant

Phi Thach is an Executive Assistant at RA Capital Management. Phi's primary responsibilities at RA Capital are to support the Operations team by coordinating calendars, events, and company meetings. Phi previously worked as an Executive Assistant at Relay Therapeutics. Prior to Relay, she worked as an Executive Assistant at Bullhorn, Inc. Phi holds an Associate in Science Business Administration from Middlesex Community College.

TJ WARWICK

Senior Fund Accountant

TJ is a Senior Fund Accountant at RA Capital Management. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. Prior to RA, TJ was at KPMG where he was a Senior Audit Associate. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. TJ has a BS in Business Administration with a concentration in Accounting from Northeastern University.

BETHANY WRIGHT

Senior Finance Associate

Bethany is a Senior Finance Associate at RA Capital Management. Her primarily responsibilities are to assist with all finance operations related to the Firm. She previously held posts as an Accounts Receivable Analyst at the MFA Companies and as an Administrative Assistant at the Massachusetts Eye and Ear Infirmary. She holds a BS in Corporate Finance & Accounting from Salem State University.

ALLY BOERTZEL

Executive Assistant

Ally Boertzel is an Executive Assistant at RA Ventures (RAVen). Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners and Entrepreneurs-In-Residence within RAVen. Ally brings to RAVen nearly a decade of administrative experience. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. Prior to Akebia, she gained Administrative and Resource Management experience at Wellington Management and Signature Consultants, respectively. Ally coached Women's Lacrosse at Muhlenberg College in PA. Prior to her stint coaching, she received her BS in Psychology with a Minor in History from Union College in NY.

NATALIE CAMACHO

Executive Assistant

Natalie Camacho is an Executive Assistant at RA Ventures (RAVen). Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners within RAVen. Natalie brings to RAVen more than six years of Administrative experience. Prior to RAVen, Natalie served as an EA for three years at Massachusetts Technology Collaborative (MassTech), a Boston agency supporting business formation and growth in the state's technology sector. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. Natalie holds a BA in Psychology from William Paterson University and a MA in Psychology from Seton Hall University.

HABIB DABLE

Venture Partner

Habib Dable is a Venture Partner at RA Ventures (RAVen), focusing on advising and supporting newcos, portfolio companies and executives within RAVen. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Prior to joining RAVen, Habib spent five years as President and CEO at Acceleron Pharma. In this role, he propelled the company to the next stage of growth and increased shareholder value by altering the course of this formerly research-based company to prioritize innovation, speed to commercialization, and culture transformation. While at Acceleron he successfully launched the company's first blockbuster asset - REBLOZYL® - and brought in the company's lead drug - Sotatercept - prior to Acceleron's eventual sale to Merck in 2021. Prior to Acceleron, Habib held various leadership roles at Bayer AG during his ~22-year tenure with the company. As President, U.S. Pharmaceuticals at Bayer, he directed a multi-billion-dollar portfolio of products across multiple therapeutic areas (cardiovascular disease, hematology, neurology, oncology, and women's health). Prior to that, he held roles as Executive Vice President, Global Head Specialty Medicine and Vice President, Ophthalmology/Global Launch Team Head, EYLEA®. Habib received his BBA in Marketing & Finance and his MBA in International Business from University of New Brunswick. He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/Ferry International. Habib has earned his Director Professionalism® Certificate from the National Association of Corporate Directors.

CONY D'CRUZ

Venture Partner

Cony D'Cruz is a Venture Partner at RA Ventures. Prior RA, Cony was Executive Vice President and Chief Business Officer at Schrödinger for eight years, responsible for business development involving strategic collaborations and new company formation as well as software sales in the US and Japan. Prior to Schrödinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. Prior to Proteros, Cony was Senior Vice President, Business Development, North America for Evotec and was responsible for managing all commercial activities of Evotec in North America. In these commercial roles, he initiated innovative discovery deal structures with venture companies, research foundations, and large integrated deals with pharmaceutical companies. Prior to Evotec, Cony worked at IGEN, where he was responsible for the marketing strategy of the life sciences division; in addition, he was involved in investor presentations and fundraising. Prior to IGEN Cony worked for Corning in the US and in Europe. At Corning, he held a number of sales and marketing roles with increasing responsibility; in his last position at Corning, Cony was responsible for marketing at a new business unit focused on high-throughput screening and molecular biology products. Cony received a BSc in Applied Biology from the University of London and an MBA from The Open University, Milton Keynes UK.

MILIND DESHPANDE, PhD

Venture Partner

Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. He is the co-founder and Chairman of the Board of Directors of Spero Therapeutics, and past President, CEO and member of the Board of Directors of Achillion Pharmaceuticals. Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience. He is the co-inventor of first-in-class HCV NS5A inhibitors, which led to the approval of DaklinzaTM, the first marketed drug in its class. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. Milind attended the residential Executive Program at The Wharton School of Management.

RAMIN FARZANEH-FAR, MD

Venture Partner

Ramin Farzaneh-Far is a Venture Partner at RA Capital where he works closely with RA’s Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. A trained cardiologist, he has held academic faculty positions at the University of California, San Francisco (UCSF) and the University of Texas Southwestern Medical Center. Ramin completed his internal medicine residency at Brigham & Women’s Hospital in Boston and trained in cardiovascular medicine at UCSF. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF.

COSMAS GIALLOURAKIS

Venture Partner

Cosmas Giallourakis is a Venture Partner at RA Ventures, focusing on new company creation. Cosmas brings to RAVen over a decade of leadership experiences at the interface of basic science, drug development and clinical care. Prior to RAVen, Cosmas was an Entrepreneur in Residence at Third Rock Ventures and was part of the teams that built Asher Bio (cell targeted biologics for oncology/autoimmune diseases) and Septerna (GPCR focused drug discovery) as well as other NewCOs in development. In addition, Cosmas has co-founded companies including Design Pharma (synthetic bio) and a company in stealth focused on RNA based genetic medicines. Prior to this, Cosmas was a Director at Takeda Pharmaceuticals where he was responsible for developing multiple partnerships and platforms on emerging technologies, along with leading drug development teams in cell and gene therapies. Before transitioning to industry, Cosmas was a faculty member at Harvard Medical School/Massachusetts General Hospital (MGH), where he had an active gastroenterology clinical practice and ran a lab whose research centered on fundamental aspects of RNA and epigenetics. Cosmas’s academic research has been published in journals such as Cell, Science, and Nature. Cosmas received his BS in Physics from Massachusetts Institute of Technology and his MD from Rutgers-New Jersey Medical School. He completed his residency in internal medicine at Yale-New Haven Hospital and completed his clinical gastroenterology fellowship at Massachusetts General Hospital / Harvard Medical School as well post-doctoral training with Frederick Alt, an HHMI investigator, in molecular immunology.

EMILY GRANSKY

VP, Recruiting

Emily Gransky is VP of Recruiting at RA Ventures (RAVen). In this role, Emily works closely with senior leaders, Venture Partners and Managing Directors within the Venture Team at RA Capital within RAVen. Her primary responsibility is leading and executing full cycle recruiting across all newcos and portfolio companies. Prior to RAVen, Emily worked as Director, Talent Acquisition, at Generation Bio. During this time, she led the hiring of ~60 new team members, built/implemented an ATS and Analytics Dashboard, created a Recruiting SharePoint site with talent acquisition resources, and developed a strategy to increase retention and engagement. Prior to Generation Bio, Emily served as Director, Talent Acquisition and Operations at Flagship Pioneering, a role in which she built talent systems to support the growth of 30+ pre-series B biotech startup companies. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio. While in these roles, Emily helped Bluebird grow from 300 to 1000 employees. Emily has her BS in Chemical Engineering from Rensselaer Polytechnic Institute in NY.

EMILY MINKOW

Venture Partner

Emily Minkow is a Venture Partner at RA Ventures. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics from the company’s inception in 2017 until its acquisition by Eli Lilly in 2021. At Prevail, Emily led business functions including business development, strategy, commercialization, public relations, patient advocacy, and intellectual property, and co-led financings generating $250 million in proceeds, including the company’s IPO in 2019. Previously, Emily spent over seven years at Celgene Corporation in positions of increasing responsibility in business development, marketing, operations, and as Principal to the Chairman and CEO. As Executive Director of Business Development at Celgene, Emily was responsible for all aspects of deal evaluation, negotiation, and execution for licensing deals, mergers and acquisitions, and collaborations, with a focus on immune-inflammatory and neurodegenerative diseases. As Director of Global Marketing, she provided global leadership for the launch of Otezla for the treatment of patients with psoriasis and psoriatic arthritis. Emily started her career in strategy consulting at Frankel Group. She received a BA from Princeton University and an MBA from Harvard Business School.

MEGHAN PETROWSKI

Business Operations Manager/Recruiting Coordinator

Meghan Petrowski is an Business Operations Manager / Recruiting Coordinator at RA Ventures (RAVen). Her primary responsibilities are to coordinate with all of RAVen’s operational teams to manage and execute critical operations, implement projects across functions, and assist in recruiting efforts for RAVen. Meghan previously worked as an Executive Assistant at Silversmith Capital Partners and as the Associate Athletic Director at the Academy of Art University. Meghan has a BA in American Studies from the University of California, Berkeley and played on the women's lacrosse team.

SOUMYA RAY, PhD

Entrepreneur In Residence

Soumya Ray is an Entrepreneur In Residence at RA Ventures and a Co-founder and Head of Computation of a stealth newco within RA Ventures. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. He works closely with RA's Investment Team on novel drug discovery platforms with emphasis on computational chemistry and machine learning. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. Soumya completed his postdoc at Brigham and Women’s Hospital and held an Assistant Professor of Neuroscience role at Harvard Medical School Neurology Department where he contributed to the Harvard Neurodiscovery Center’s (HNDC) academic drug discovery initiative as a modeler and drug hunter. Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development. Soumya spent time as an EIR at IncTank Ventures, where he worked on multiple company creations. After his stay at IncTank Ventures, he joined Schrödinger’s Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. After leaving Schrodinger in 2018, Soumya founded 3-Dimensional Consulting, a boutique Physics Based and Machine-Learning focused computational chemistry consulting firm that provides scientific support for early-stage drug discovery and company formation within various Boston-based venture firms including: Atlas Venture, 3rd Rock, MPM Capital, and RA Capital. Soumya has contributed to over 75 drug discovery programs ranging from small startups to large pharma, leading to nine development candidates currently in various stages of clinical trials. He has over 20 academic publications, inventorship on numerous patents, and serves as reviewer for multiple journals and NIH grants committee. Soumya obtained his PhD in X-ray Crystallography and Biophysics from the Indian Institute of Science while working as visiting research scholar at Rockefeller University.

MICHAEL ROSENZWEIG DVM, PhD

Entrepreneur in Residence

Michael Rosenzweig is an EIR at RA Capital. In this role he works closely with the Venture Team to evaluate drug discovery platforms and initiate novel therapeutic programs. Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. Prior to joining RA, Michael was Associate Vice President at Merck Research Labs. In this position, he played a critical role in building Merck’s oncology pipeline into one of the most robust in cancer immunotherapy, focusing on a modality-agnostic strategy with a broad biology of targets and Keytruda combination strategies. He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. Michael earned a DVM at the University of Pretoria and a PhD in Immunology at the University of Pennsylvania.

J. MICHAEL RYAN, MD

Entrepreneur in Residence

Michael Ryan is an EIR at RA Capital. He most recently served as Chief Medical Officer for Rodin Therapeutics, where he led all clinical development activities from first-in-human through patient studies until the acquisition by Alkermes. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. He completed an internship in Internal Medicine and residency in Psychiatry at the University of Utah Health Sciences Center. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004.

GERALD SEWACK, PhD

Vice President of Scientific Operations

Gerald is Vice President of Scientific Operations at RA Ventures (RAVen). In this role, Gerald is responsible for evaluating new technology and novel biology to originate and support the generation of new companies in collaboration with RAVen’s Venture Partners and EIRs. He also supports select RAVen portfolio companies in active strategic operating roles and serves as Board Director for GIVax, Summation Bio, and Astro Therapeutics. Prior to this, Gerald was Director of Scientific Operations for RA Capital. He worked previously at Global Prior Art, an intellectual property analysis firm, as a Partner and the Director of the Life Sciences Division. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. His research investigated chromatin structure and transcription factor binding.

NADIM SHOHDY, PhD

Entrepreneur in Residence

Nadim Shohdy is an EIR at RA Capital. In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. Nadim has 11+ years’ experience in commercializing drug discovery across diverse indications and modalities. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. Prior to co-founding Therapeutics Alliances, Nadim worked in NYU’s Industrial Liaison technology transfer group, and was a Research Analyst at the International AIDS Vaccine Initiative. Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University.

JOEL C. BARRISH, Ph.D.

Advisor

Joel is currently President and Chief Scientific Officer at Jnana Therapeutics, a company focused on unlocking hard-to-drug targets, including solute carrier proteins (SLCs). Prior to Jnana, Joel served as Chief Scientific Officer at Achillion Pharmaceuticals, where he led discovery efforts on Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy. Most of Joel’s career was spent as a medicinal chemist in pharma, where he capped a 28-year career at Bristol-Myers Squibb by spending the last five years as Vice President and Head of Discovery Chemistry, working across all therapeutic areas. In that role, Joel worked with teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. He is a co-author on over 130 peer reviewed publications and is a co-inventor on 40 issued U.S. patents. Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelor’s in Chemistry from the University of Pennsylvania.

MIKE CLOONAN

Advisor

Mike is President and Chief Executive Officer of Sionna. He is a respected biotech leader with over twenty years of biopharma experience across global organizations. Most recently he served as Chief Operating Officer at Sage Therapeutics leading all the business functions (commercial, medical affairs, government affairs, business development, technical operations, strategy and program management) and G&A functions. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the company’s first product, and execution of a transformational, multi-billion collaboration.

Prior to Sage, he had a 14-year tenure at Biogen in various business and commercial roles. His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the MS, hemophilia, and SMA franchises. Prior to Biogen, Mike worked at Bain & Company as a consultant specializing in healthcare. Mike earned his MBA from the Darden Graduate School of Business Administration

DANIEL GRAU

Advisor

Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. He is also an Advisor to HotSpot Therapeutics and recently served on the Board of Directors at Research Alliance Corporation I (merged with POINT Biopharma) and at TetraGenetics (acquired by AbCellera). Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). He also served as member of the Product Advisory Board at Concert Pharmaceuticals and as an Advisor to Nimbus Therapeutics. Early in his career, Mr. Grau worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product launch. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities.

SADIK KASSIM. PhD

Advisor

Sadik Kassim is a scientist and executive with extensive experience in the biotechnology industry with a specific focus on cell and gene therapy bioprocessing and translational research. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. Most recently, he was Chief Technology Officer at Vor Bio where he built the technical operations team responsible for process development, analytical development, supply chain and manufacturing support of a CRISPR gene-edited HSPC product and oversaw the company’s CAR-T efforts. Prior to Vor, Sadik served as Executive Director at Kite Pharma and led the development of manufacturing processes for autologous CAR-T and TCR-based cell therapies. As the Chief Scientific Officer at Mustang Bio, Sadik managed the foundational build-out of the company’s preclinical and manufacturing activities. Earlier in his career, he was Head of Early Analytical Development for Novartis’ Cell and Gene Therapies Unit and worked on research teams at the National Cancer Institute with Dr. Steven Rosenberg, the University of Pennsylvania Gene Therapy Program with Dr. Jim Wilson, and Johnson and Johnson’s Immunology Discovery group. Sadik and his teams have contributed to the successful BLA and MAA applications for three of the commercially available CAR-T therapies: Kymriah®, Yescarta®, and Tecartus®. Sadik holds a bachelor of science degree in Cell and Molecular Biology from Tulane University, and earned his PhD in Microbiology and Immunology from Louisiana State University.

PATRICK TROJER, PhD

Advisor

Patrick joined TRIANA Biomedicines in December of 2021 as President & CEO and Board member after a successful career at Constellation Pharmaceuticals where he served as the company’s CSO. As a founder and member of Constellation’s executive team Patrick materially contributed to several successful financing rounds and deals, including a crossover round, an IPO and the ultimate acqusition of the company. Patrick was instrumental to building Constellation‘s discovery platform, establishing a portfolio of competitive clinical candidates and drove the maturation of the company‘s development efforts, leading to one PhIII and two PhII assets and three additional clinical candidates. Prior to this, he was a Postdoctoral Fellow at NYU Medical School in the laboratory of Dr. Danny Reinberg, exploring the functional downstream consequences of changes to the histone posttranslational modification landscape on processes that require access to DNA, including the regulation of gene expression. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria.

JESSE CHEN, PhD

Jesse Chen is an EIR at RA Capital. In this role he works closely with RA’s Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Jesse has more than a decade of discovery research and management experience, from early discovery through preclinical development. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. As the first and founding member of Kymera’s scientific team, Jesse was responsible for building the company’s industry-leading targeted protein degradation platform and pipeline, and he helped secure the company’s Series A and B financings as well as a partnership with Vertex. Jesse also held research leadership roles at Moderna Therapeutics and Millennium Pharmaceuticals, where he was responsible for developing novel platforms and leading discovery programs. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow.

BEN DAKE, PhD

Ben Dake is a Venture Associate at RA Capital Management. Ben’s primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Ben has also mapped competitive landscapes with a focus on cardiovascular diseases and regenerative medicine as a member of the Cardio-Renal Team within the TechAtlas division of RA Capital. Ben holds a BS in Biology and an MS in Virology from the University of Nebraska, Lincoln, and a PhD in Cancer Biology from the Tufts University School of Medicine. His doctoral research focused on breast cancer metastasis. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Women’s Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization.

DANIELLE FELDMAN, PhD

Danielle Feldman is an Entrepreneur-in-Residence at RAVentures and was a Co-Founder and Associate Director of Corporate Development at AthenenTx, a neuro-focused RA-funded NewCo that spun out in 2019. She has a PhD in Neuroscience from MIT and prior to her time at Athenen, she worked as an Associate on the Tech Atlas team at RA Capital, covering Neuro, GI, and Orphan indications.

VIKRAM SHEEL KUMAR, MD

Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. He is co-founder and CEO of Clear Creek Bio, an RA Capital portfolio company. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. He was named an MIT Technology Review 100 innovators under 35 for his MIT Media Lab social enterprise, Dimagi, that has impacted millions with its mobile data collection platform. Vikram trained in clinical pathology at the Brigham and Women’s Hospital where he was chief resident.

JAMES McARTHUR, PhD

James McArthur is an Advisor for RA Capital Management. James was most recently the founder, Chief Executive Officer, and served as a Board Director for Imara, a public company developing therapies for sickle cell disease and β-thallasemia. He was also the co-founder and President of Research and Development of Cydan, a rare disease accelerator. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. Prior to these companies, James held senior research leadership roles in the gene and stem cell therapy companies Cell Genesys, Phylogix, and Somatix Therapy. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group. James was a post-doctoral fellow at Massachusetts Institute of Technology and University of California, Berkeley. He worked with Dr. David Raulet and Nobel Laureate Dr. James Allison before which he received a PhD in Molecular Oncology and BSc in Biochemistry from McGill University in Montreal.

TIMOTHY NOYES, MBA

Timothy Noyes is an Advisor for RA Capital Management.  RA Capital and CEO of Arcuate Therapeutics. In this role he works closely with RA’s Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Timothy is a veteran biotech leader with deep experience in growing companies and bringing innovative therapies to market. Prior to joining RA Capital and Arcuate Therapeutics, Tim was President and CEO of Proteon Therapeutics, a company focused on developing novel therapeutics to improve the lives of patients with kidney and vascular diseases. Tim was hired as the fourth employee at Proteon and built a team that brought an innovative biologic for blood vessel remodeling from pre-clinical through two Phase 3 clinical trials. Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. Tim was responsible for building the commercial team at GelTex and launching Renagel, a novel treatment for patients with kidney failure that grew to a $1B franchise . After the acquisition, Tim was named President of Genzyme’s Renal Division and GelTex Pharmaceuticals. Tim began his career at Merck & Co., serving in multiple commercial roles in its cardiovascular, gastrointestinal, and managed care divisions. Tim received his A.B. from Harvard College and an M.B.A. from Harvard Business School.

ALONSO RICARDO, PhD

Alonso Ricardo is an Entrepreneur in Residence at RA Capital, where he works closely with RA’s Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Prior to joining RA Capital, Alonso was Chief Technology and Innovation Officer at Ra Pharmaceuticals until it was acquired by UCB in 2020. At Ra Pharma, Alonso held various leadership roles where he initiated and led the scientific efforts for the company in multiple preclinical and clinical programs; working in a wide set of therapeutic areas and using different molecular modalities. In this role, he gained broad expertise across all phases of drug discovery, early development, and clinical research. Alonso completed his Ph.D. in Chemistry at the University of Florida and his post-doctoral work as a Howard Hughes Medical Institute Fellow at Harvard University and the Massachusetts General Hospital. Alonso was also a chemistry professor at the Universidad de los Andes in Colombia.

ADAM ROSENBERG

Adam Rosenberg is an Advisor for RA Capital Management. Adam was most recently President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Adam was also an advisor and investor in “A Late Quartet”, an entrepreneurial feature film centered on a cellist diagnosed with Parkinson’s disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College.